TY - JOUR
T1 - Treatment of autoimmune liver disease
T2 - current and future therapeutic options
AU - Trivedi, Palak J
AU - Hirschfield, Gideon M
PY - 2013/5
Y1 - 2013/5
N2 - Autoimmune liver disease spans three predominant processes, from the interface hepatitis of autoimmune hepatitis to the lymphocytic cholangitis of primary biliary cirrhosis, and finally the obstructive fibrosing sclerotic cholangiopathy of primary sclerosing cholangitis. Although all autoimmune in origin, they differ in their epidemiology, presentation and response to immunosuppressive therapy and bile acid based treatments. With an ongoing better appreciation of disease aetiology and pathogenesis, treatment is set ultimately to become more rational. We provide an overview of current and future therapies for patients with autoimmune liver disease, with an emphasis placed on some of the evidence that drives current practice.
AB - Autoimmune liver disease spans three predominant processes, from the interface hepatitis of autoimmune hepatitis to the lymphocytic cholangitis of primary biliary cirrhosis, and finally the obstructive fibrosing sclerotic cholangiopathy of primary sclerosing cholangitis. Although all autoimmune in origin, they differ in their epidemiology, presentation and response to immunosuppressive therapy and bile acid based treatments. With an ongoing better appreciation of disease aetiology and pathogenesis, treatment is set ultimately to become more rational. We provide an overview of current and future therapies for patients with autoimmune liver disease, with an emphasis placed on some of the evidence that drives current practice.
U2 - 10.1177/2040622313478646
DO - 10.1177/2040622313478646
M3 - Article
C2 - 23634279
SN - 2040-6223
VL - 4
SP - 119
EP - 141
JO - Therapeutic advances in chronic disease
JF - Therapeutic advances in chronic disease
IS - 3
ER -
